Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Nanotherapy offers new hope for the treatment of Type 1 diabetes
    18 January 2022

    Nanotherapy offers new hope for the treatment of Type 1 diabetes

    Individuals living with Type 1 diabetes must carefully follow prescribed insulin regimens every day, receiving injections of the hormone via syringe, insulin pump or some other device. And without viable long-term treatments, this course of treatment is a lifelong sentence.

  • 17 January 2022
    Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson Injection

    Glenmark Pharmaceuticals Inc., USA (Glenmark) has received tentative approval by the United States Food & Drug Administration (U.S. FDA) for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single-Dose Pre-Filled Syringe, the generic version of Lexiscan®1 Injection, 0.4 mg/5 mL (0.08 mg/mL), of Astellas US, Inc.

    According to IQVIATM sales data for the 12 month period ending November 2021, the Lexiscan® Injection, 0.4 mg/5 mL (0.08 mg/mL) market2 achieved annual sales of approximately $659.9 million*.

  • 17 January 2022
    IIHMR University, Jaipur selected globally for second phase of TDR Postgraduate Training Scheme to train the next generation of public health leaders

    IIHMR University, Jaipur has been selected from India to implement the second phase of TDR’s Postgraduate Training Scheme (2022-2026). TDR’s Postgraduate Training Scheme will provide a full academic scholarship though IIHMR University for selected students from Low- and Middle-Income Countries (LMICs). Students will obtain master’s degrees focused on implementation research on malaria, TB and neglected tropical diseases.

  • 12 January 2022
    CuraTeQ and Orion expand licensing deal for biosimilars distribution in select European markets

    Aurobindo Pharma Limited announced that its subsidiary CuraTeQ Biologics Pvt Ltd. has expanded the scope of its marketing and distribution agreement with Orion Corporation (Orion) to commercialize its biosimilars pipeline to include the Baltic states in Europe. Earlier in 2020, CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia.

  • 12 January 2022
    New Method to Increase Effectiveness of Nanomedicines

    Researchers at Penn Medicine have discovered a new, more effective method of preventing the body’s own proteins from treating nanomedicines like foreign invaders, by covering the nanoparticles with a coating to suppress the immune response that dampens the therapy’s effectiveness.

  • 12 January 2022
    Macrophages are fighting against plaque formation in the artery, suggests study

    A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters "good" macrophage behaviour within the vessel wall.

  • 12 January 2022
    Webinar on Meeting Indias Target of Eradication of TB by 2025 by Testing and Treating the Missing Millions with Tuberculosis

    IIHMR University a premier Health Care Research institution with a prime focus on delivering skill-based knowledge and about the future of healthcare organised a Webinar – Meeting India’s Target of Eradication of TB by 2025 by Testing and Treating the Missing Millions with Tuberculosis.

  • 11 January 2022
    EU approves Lumykras on conditional basis for lung cancer

    Amgen announced that the European Commission has granted conditional marketing authorization for LUMYKRAS® (sotorasib), a first-in-class KRASG12C inhibitor, for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

  • 11 January 2022
    Carisma engineered macrophage technology with Modernas mRNA and LNP technologies to generate and develop in vivo CAR-M therapeutics

    Moderna Inc a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Carisma Therapeutics Inc., a biopharmaceutical pioneer in engineered macrophage-based therapeutics, announced that the two companies have entered into a strategic collaboration agreement to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for the treatment of cancer.

  • 11 January 2022
    Fosun Pharma and Insilico Medicine joined for AI-driven discovery of four biological targets

    Shanghai Fosun Pharmaceutical (Group) Co., Ltd a leading innovation-driven international healthcare group in China and Insilico Medicine an end-to-end artificial intelligence (AI)-driven drug discovery and development company, entered into a collaboration agreement to advance the discovery and development of drugs targeting a number of different targets globally through the use of AI technology.

Subscribe to Pharma News